Slider3
Data driven

Machine and Deep Learning algorithms designed to assist cardiac electrophysiologists
during interventions

Slider3
Robust and accurate

VX1 drastically reduces inter-operator variability

Slider1
Real time assistance

VX1 provides a real time analysis of electrograms corresponding to the one of a collective of trained cardiac electrophysiologists

Slider4
Extended compatibility

With most mapping catheters, EP recording and 3D navigation systems

Slider5
Safe and tailored

As we all are unique, every patient’s arrhythmia is unique

About Volta

Volta Medical leverages artificial intelligence to revolutionize interventional cardiac electrophysiology. Its cutting-edge software solutions use machine and deep learning algorithms to assist operators during cardiac ablation procedures.
Volta’s DNA is to provide physicians with solutions that are user-friendly. Its first medical device, VX1, consists of a cue-giving interface designed to facilitate the identification of abnormal electrograms during ablation of complex arrhythmias such as atrial fibrillation. With VX1, operators keep their go-to navigation system and catheters.
The VX1 real-time analysis algorithm has been trained on carefully curated databases of annotated intra-cardiac electrograms. The solution may be used as a support to assist electrogram-based atrial fibrillation ablation.
VX1 is CE marked and FDA cleared. VX1 was the first artificial intelligence-based software solution to be FDA cleared in the interventional cardiology space.
Volta Medical is expanding at a fast rate across the globe. Multiple partnerships have been formed with leading centers in Europe and the US.
Timeline

Non Dispersed Electrocardiograms

Dispersed Electrocardiograms

Bolt Bolt

1

dispersion location

Multipolar electrogram abnormality associated with the perpetuation of atrial fibrillation. Red: highly dispersed electrograms, Orange: dispersed electrograms, Blue: non-dispersed electrograms.

2

mapping catheter

Steerable, multipolar electrode catheter. Allows for the recording of the local electrical activity.

3

reference cycle length

Atrial cycle length estimated from recordings obtained with the coronary sinus catheter.

4

mapping cycle length

Local cycle length estimated from real-time recordings obtained with the mapping catheter.

Non Dispersed VX1 Dispersed VX1 VX1 Marker VX1 Marker VX1 Marker VX1 Marker
Mobile VX1 Mobile Non Dispersed VX1 Mobile  Dispersed VX1

1

dispersion location

Multipolar electrogram abnormality associated with the perpetuation of atrial fibrillation. Red: highly dispersed electrograms, Orange: dispersed electrograms, Blue: non-dispersed electrograms.

2

mapping catheter

Steerable, multipolar electrode catheter. Allows for the recording of the local electrical activity.

3

reference cycle length

Atrial cycle length estimated from recordings obtained with the coronary sinus catheter.

4

mapping cycle length

Local cycle length estimated from real-time recordings obtained with the mapping catheter.

Compliance

Patient privacy: All data collected is anonymized or pseudonymized in compliance with Data Protection regulations. Notably, data undergoes a state-of-the-art encryption (dual process, dual keys). Our policy meets the highest standards of data protection.

CE marked & FDA cleared: Volta’s VX1 software solution is the first AI-based solution in the interventional cardiology space to have obtained FDA clearance and CE marking.

Technology

Real time analysis: VX1 provides state-of-the-art analysis in real-time, ensuring optimal usability.

Precision: its integration allows for high density mapping in both atria.

Intellectual Property: Volta’s technology is protected internationally with multiple patents.

Data Driven: VX1 algorithm has been trained on large, carefully curated databases. Our goal is to mimic the expertise of trained physicians and reduce inter-operator variability in identifying specific abnormal electrograms.

Compatibility

Most multipolar mapping catheters

Two EP recording systems

Most 3D navigation systems

Logo Row

VX1. vs. Trained Expert Cardiac Electrophysiologists

VX1 Cardiac Electrophysiologist

Conclusions

VX1 has the potential to bring the expertise of a multi-year-trained electrophysiologist physician in identifying dispersed electrograms to every patient.
In real time, VX1 matches the expert analysis of trained physicians who were given an unlimited time for their analysis.

SOURCE: HRS 2020 Imagineer Tech Showcase.

-

The clinical significance of utilizing the VX1 software to help identify areas with intra-cardiac atrial electrograms exhibiting spatiotemporal dispersion
for catheter ablation of atrial arrhythmias, such as atrial fibrillation, has not been established by clinical investigations.

surgeon using volta

Our team

Left_Arrow Right_Arrow

Management

Profil_Pic

Théophile Mohr Durdez

CEO, co-founder

+

Profil_Pic

Théophile Mohr Durdez

CEO, co-founder

Théophile grew up in France, Germany and Austria. Since his young age, he wanted to help his fellow humans with technology. Latter on, he studied at Ecole polytechnique (Paris), where he fell in love with Statistics, Machine and Deep Learning. There, he obtained a double degree with the Business School HEC (Paris).

His first accomplishment was to create a wheelchair controlled via eye-tracking for SLA disabled people. He then helped in solving complex geophysics with the use of differential equations.

In 2016, he co-founded Volta, where he was the passionate architect and inventor of Volta’s algorithms. In 2017, Théophile received the Research Award from Ecole polytechnique for the algorithms that he developed at Volta.
Théophile is hiring and leading a team of top-talents to drive Volta towards success by making a difference for operators and patients.

Profil_Pic

Julien Seitz

President, co-founder

+

Profil_Pic

Julien Seitz

President, co-founder

Julien is the acting Chief of the cardiac electrophysiology section at Saint Joseph Hospital (Marseille, France).

St-Joseph hospital is one of the three highest-volume ablation center in the country. This gave him many opportunities to think deep about what interventional cardiologists need most. Julien is well-known for his contributions to the field of electrogram-based ablation. He has published plenty of manuscripts in high-impact cardiology journals. He is a regular guest speaker, chairman at major conferences.

Since he started as an interventional cardiologist, Julien has been obsessed with making accessible any complex ablation approach to large numbers of colleague physicians. He started with conceptualizing multipolar-electrogram visual interpretation into a series of simple steps.

Since Volta was created, he used his in-depth experience to help design AI algorithms that provide simple but powerful cues to cardiologists.

Profil_Pic

Jérome Kalifa

Chairman, CMO, co-founder

+

Profil_Pic

Jérome Kalifa

Chairman, CMO, co-founder

Both basic scientist and clinical electrophysiologist, Jérôme is based in the USA and currently Faculty at Brown University, Rhode Island, USA.

Jérôme dedicated about two decades to translational and clinical research in cardiac electrophysiology.
He is a seasoned speaker, chairman and reviewer for cardiology journals and conferences. His research effort has focused on understanding atrial fibrillation mechanisms as they pertain to cardiac interventions.

His background in cardiac mapping, imaging, database management and catheter technologies helped us design Volta’s algorithms.

Jérôme’s knowledge of the US clinical landscape is helping Volta address the needs of US users.

Profil_Pic

Clément Bars

VP, co-founder

+

Profil_Pic

Clément Bars

VP, co-founder

Clément has devoted his career to refining his understanding of procedural work flows in the field of cardiovascular electrophysiology.

Clement has become a well-known expert at simplifying work flows, specifically as they pertain to atrial fibrillation catheter ablation. His many contributions to the field of ablation could be summarized as “Do what you understand well, but keep it simple”.

He is regularly invited as a guest speaker or as a proctor in major hospitals in Europe, USA and Asia.

At Volta, he oversees the clinical evaluation of Volta’s algorithms. With more than 40 cardiac electrophysiologists visiting us last year alone, Clément has formed a large network of interventional cardiologists that cannot wait to try Volta’s algorithms.

Profil_Pic

Paola Milpied

VP Clinical & Regulatory Affairs

+

Profil_Pic

Paola Milpied

VP Clinical & Regulatory Affairs

Paola is a former engineer and data scientist who holds a PhD in signal processing and machine learning applied to Cardiology. She has 13+ years of experience in medical device companies in France and in the US where she held several roles in clinical research and regulatory affairs in the cardiovascular field.
At Volta, Paola leads the clinical, quality and regulatory affairs department with an ambitious clinical program as well as major regulatory challenges.

Profil_Pic

Laurent Launay

VP Engineering

+

Profil_Pic

Laurent Launay

VP Engineering

Ph.D. in Computer Science

24+ years of experience in GE Healthcare and IRT b-com

Worked as Senior Manager for 3D applications, workstations applications and platforms

Profil_Pic

John Slump

CFO

+

Profil_Pic

John Slump

CFO

Founder/CFO of multiple med-tech companies including FARAPULSE acquired by Boston Scientific Experienced medical devices & health tech operator

Raised >$100M of total startup financing and returned >$500M of exit value to shareholders with an attractive ROI

Profil_Pic

Jeff Martin

VP of Global Marketing

+

Profil_Pic

Jeff Martin

VP of Global Marketing

20 years of experience in med device marketing.

Previously Marketing Director at Acutus; Group Product Director at Biosense Webster.

Highly effective in development and execution of global strategic marketing/field team plans.

Profil_Pic

El Makki Voundy

Full-Stack Developer

Profil_Pic

Fabienne Pouplier

DPO

Profil_Pic

Mohsen Shah

Director of US Operations

Profil_Pic

Daniel Guerrero

US Clinical Operations Manager

Profil_Pic

Didier Villevalois

Full-Stack Developer

Profil_Pic

Philippe Tartaise

Software Engineering Manager

Profil_Pic

Sabrina Siame

Clinical Research Assistant

Profil_Pic

Aman

Business Analyst

Profil_Pic

Loren Siry

HR Manager

Profil_Pic

Dinara Veshchezerova

Data Scientist

Profil_Pic

Mélanie Reist

Field Technical Engineer

Profil_Pic

Meryem Serdi

Field Technical Engineer

Profil_Pic

Maxime Basset

Field Technical Engineer

Profil_Pic

Yoann Dutil

QMS Compliance Manager

Profil_Pic

Audrey Balzano

Executive Assistant

Profil_Pic

Thomas Boudou

Data Scientist

Profil_Pic

Camille Schmisser

Clinical & Regulatory Affairs Specialist

Profil_Pic

Idriss Lopes Sanches

Full Stack Developer

Profil_Pic

Aurélien Rosiau

Full-Stack Developer

Profil_Pic

Vianney Guesdon-Vennerie

Front-End Developer

Profil_Pic

Denis Hansjacob

COO

+

Profil_Pic

Denis Hansjacob

COO

After more than 30 years as a high-level executive in the Biomedical Device Industry, Denis decided to join Volta to be part of the next wave of technology designed for the operating room.

Denis has been Managing Director of St. Jude Medical France and Vice-President for Northern Europe, where he led commercial operations. He has a unique understanding of marketing, sales and reimbursement mechanisms. Denis is helping Volta’s products spread quickly in Europe and the USA.

Also, Denis is shaping the future of biomedical devices revenue model. Denis is the proponent that AI is the best solution to cure more patients from AF in the best cost efficient way.

Profil_Pic

Anthony Appetiti

Head of Sales EU

Profil_Pic

Rebecca Sircoulomb

Head of product

Investors & Partners

Pasteur Mutualité Guilde Vensana
Lightsone bpifrance Polytechnique HEC

Press releases

Left_Arrow Right_Arrow

Volta Medical Secures €36M in Series B Funding to Support Adoption of its AI Software for Cardiac Ablation, New CFO Introduced

Volta Logo

Volta Medical Secures €36M in Series B Funding to Support Adoption of its AI Software for Cardiac Ablation, New CFO Introduced

  •  New round of financing led by Vensana Capital will support technology platform expansion and further validating VX1, Volta’s Artificial Intelligence (AI) Decision-Support Software in improving catheter ablation for complex cardiac arrhythmias
  • Medical device executive John Slump joins as Chief Financial Officer

Marseille (France), January 5, 2023 – Volta Medical, a pioneering health technology company developing artificial intelligence (AI) solutions to assist electrophysiologist physicians in treating complex cardiac arrhythmias such as atrial fibrillation (AF), today announced €36 million in new Series B funding, bringing the total capital raised to over €70 million.

The funding round was led by U.S.-based Vensana Capital with co-investment from Lightstone Ventures and existing investor Gilde Healthcare. The funding will help accelerate new product development, support additional clinical trials, prepare for full-scale US commercialization, and pursue further regulatory approvals. The company’s lead product, VOLTA VX1, is the first commercially available AI decision-support software to help guide physicians with identification and real-time annotation of unique abnormalities (so called “dispersed electrograms“) on 3D anatomical and electrical maps of the heart.  This technology ultimately may lead to optimized catheter-ablation procedures for complex arrhythmias, including persistent AF.

“There is a critical need to improve precision and consistency in cardiac ablation procedures for patients with persistent AF.” said Theophile Mohr Durdez, Volta Medical CEO and co-founder. “With half of these patients requiring repeat treatments, clinicians need tools that enable them to better understand the disease and drastically improve patient outcomes. We believe VOLTA’s VX1 has the potential to do just that in a consistent, reproducible way. We are most grateful to the teams at Vensana, Lightstone, and Gilde for their support and confidence as we partner to further validate our products and expand access to it globally.”

“Volta Medical’s technology is designed to redefine how electrophysiologists make real-time decisions in pinpointing areas relevant to atrial fibrillation persistence,” said Justin Klein, MD, JD, co-founder and managing partner of Vensana Capital. “We applaud the team’s commitment to validating their products with an investment in multiple high quality clinical trials. We are confident that Volta’s innovative AI software will transform the effectiveness and efficiency of these challenging procedures.”

Volta Medical also is pleased to announce the appointment of experienced medical device executive, John Slump, as CFO of Volta Medical. A seasoned operator in the industry, John has a proven track record as a founder and CFO, leading multiple MedTech companies from concept through regulatory approvals, commercial growth, and strategic acquisitions. Most recently, he served as CFO of Surgical Innovation Associates, a rapidly growing medical device company in the reconstructive and plastic surgery market that was acquired by Integra LifeSciences. Prior to that, John co-founded FARAPULSE, a medical device company in electrophysiology pioneering novel pulsed field ablation technology that was acquired in 2021 by Boston Scientific. Previously, John served as CFO of Attune Medical, an emerging growth medical device company commercializing proprietary esophageal temperature management devices in electrophysiology and other surgical markets.

“I’m excited to join the Volta Medical team and am pleased with our ability to attract significant equity investment from both new and existing investors in an increasingly challenging fundraising climate,” John said. “VOLTA VX1 has the potential to make a major difference in the lives of millions of people with AF, and this Series B Financing will help to accelerate its development and adoption nationally and across the globe.”

About Volta Medical
Volta Medical is a health technology company developing artificial intelligence software solutions to assist cardiac electrophysiologists during arrhythmia treatment procedures to improve clinical outcomes for patients. Founded by three physicians and a data scientist in 2016 in Marseille, Volta’s overarching goal is to improve cardiac arrhythmia management by developing state-of-the-art, data-driven medical devices trained on large databases of procedural data with the highest standards of data protection. The company’s first product, VX1, is a digital AI companion device and algorithm to assist cardiologists with real-time identification of specific abnormal electrograms (EGMs), known as dispersed EGMs. For more information, visit the company’s website at www.volta-medical.com.

About Vensana Capital

Vensana Capital is a venture capital and growth equity investment firm dedicated to partnering with entrepreneurs who seek to transform healthcare with breakthrough innovations in medical technology. Launched in 2019, Vensana manages $550M in capital and is actively investing in development and commercial stage companies across the MedTech sector, including medical devices, diagnostics and data science, life science tools, digital health, and tech-enabled services. Vensana’s investment team has a history of successfully partnering with management teams behind industry-leading companies including Cameron Health, CardiAQ, Cartiva, CV Ingenuity, Epix Therapeutics, Inari Medical, Intact Vascular, Lutonix, Neuwave Medical, Personal Genome Diagnostics, Sequent Medical, Topera, Ulthera, Veran Medical Technologies, Vertiflex, and Vesper Medical. Learn more at www.vensanacap.com.

About Lightstone Ventures

Lightstone Ventures is a global venture capital firm investing in biotech and MedTech companies pioneering big ideas poised to transform patient outcomes. Lightstone Ventures was founded in 2012 to empower visionary entrepreneurs with the resources and operational guidance necessary to bring their innovative therapeutics and technologies to the patients who need them most. Lightstone Ventures’ investment team has led deals resulting in 19 acquisitions and 20 initial public offerings over the last two decades. The firm has offices in Boston, Mass., Menlo Park, Calif., Dublin, Ireland and Singapore. For more information, visit www.lightstonevc.com.

About Gilde Healthcare

Gilde Healthcare is a specialized healthcare investor with two fund strategies: Venture&Growth and Private Equity. The firm operates out of offices in Utrecht (The Netherlands), Frankfurt (Germany) and Cambridge (United States). Gilde Healthcare Venture&Growth invests in fast growing, innovative companies active in (bio)pharmaceuticals, healthtech and medtech that are based in Europe and North America. For more information, please visit www.gildehealthcare.com.

 

Media Contact
Jeff Martin, VP of Global Marketing
Volta Medical
jeffrey.martin@volta-medical.com

U.S. Media Contact
Glenn Silver
Finn Partners
glenn.silver@finnpartners.com

Europe Media Contact
Julia Bittner
MC Services AG
julia.bittner@mc-services.eu

France Media Contact
Caroline Carmagnol
Alize RP
caroline@alizerp.com

Volta Medical’s AI based solution for patients in atrial fibrillation achieves robust validation in first peer-reviewed publication

Volta Logo

Volta Medical’s AI based solution for patients in atrial fibrillation achieves robust validation in first peer-reviewed publication

• Volta VX1 decision support software reproduces expert-physician electrogram(EGM) analysis that can assist physicians in the real-time identification of specific abnormal electrograms in a persistent atrial fibrillation (AF) population
• After a one-year follow-up, patients demonstrated a high freedom from atrial fibrillation and from any atrial arrhythmia, 89% and 73% after an average of 1.3 procedures per patient, respectively
• VX1 allowed for robust center-to-center standardization of identification of abnormal electrograms, confirming reproducibility of results across 8 centers and 17 operators
• The Ev-AIFib study was an open-label single-arm uncontrolled study comparing the acute and long-term outcomes of 85 patients in persistent AF after ablation in regions exhibiting VX1-highlighted abnormal electrograms
• The ongoing Tailored-AF randomized controlled trial is designed to demonstrate clinical significance and compare the outcomes of VX1-guided ablation versus standard ablation

Marseille (France), 31 August 2022 – Volta Medical, a pioneering health tech company developing artificial intelligence (AI) software solutions to assist electrophysiologists to treat cardiac arrhythmias, today announced that the Journal of Cardiovascular Electrophysiology (JCE) has published peer-reviewed results from the Company’s successful Ev-AIFib-Proof-of-Concept-Study with VX1, an expertise-based AI software solution to assist operators in the real-time identification of specific abnormal electrograms (EGM) during atrial fibrillation (AF) procedures. The article titled “Artificial Intelligence Software Standardizes Electrogram-based Ablation Outcome for Persistent Atrial Fibrillation” is available at https://onlinelibrary.wiley.com/doi/abs/10.1111/jce.15657.

The study was the first large-scale clinical validation of a companion AI-based software solution that reproduces expert-physician electrogram (EGM) analysis and assists operators in the real-time identification of specific abnormal EGMs, known as dispersed EGMs, during ablation procedures in a persistent AF population. Results demonstrated that VX1 allowed for the building of standardized “Volta VX1 maps”, used as a reference for operators to conduct EGM-guided ablation. The standardization of the detection of abnormal EGMs facilitated a robust patient-to-patient and center-to-center uniformity in EGM-based ablation. No major differences between operator’s visual analysis and VX1 EGM maps were recorded, and there were no statistically significant differences between outcomes across the 8 study centers and 17 operators. Furthermore, after a one-year follow-up, patients demonstrated a high freedom from atrial fibrillation and from any atrial arrhythmia, 89% and 73% after an average of 1.3 procedures per patient, respectively. Also, notably there was acute AF termination of 88% for subjects in all centers.

“Catheter ablation is well-established as an important treatment for AF and is by far the most common cardiac ablation procedure performed worldwide. Due to the complexity of persistent AF, however, there is no uniform standard of care resulting in heterogenous approaches that yield mixed and often disappointing results associated with high recurrence rates”, said Jean-Paul Albenque, MD, Cardiac Electrophysiologist at the Clinique Pasteur, Toulouse, France, and co-author of the study. “Strategies using EGM assessment to guide ablation visually, rely heavily on the individual experience of the treating electrophysiologist to identify relevant areas making outcomes highly operatordependent.”

With VX1, Volta has developed the first commercially available companion AI decision support software to assist operators in the real-time annotation of 3D anatomical and electrical maps of human atria for the presence of multipolar intra-cardiac atrial abnormal EGMs during atrial fibrillation or atrial tachycardia. The cutting-edge software solution uses machine learning including deep learning algorithms to detect abnormal signals and thus highlights potential regions of interest during AF ablation procedures. The system works in real time and identifies specific abnormal EGMs, known as dispersed EGMs. Théophile Mohr Durdez, CEO and Co-Founder of Volta Medical, added: “The publication of these peer-reviewed trial results provides further validation of our approach – to leverage AI with cutting-edge software solutions and assist operators during cardiac ablation procedures. Over 1000 procedures have so far been supported in the EU and US by VX1 and based on clinician’s feedback and clinical results, we are confident that this approach will ultimately contribute to make ablation outcomes significantly more reliable.”

Based on these encouraging results, Volta Medical has initiated the TAILORED-AF trial, the first randomized controlled clinical trial to evaluate VX1-guided ablation compared to a ‘standard of care’ anatomical ablation approach. The aim of the study is to confirm the clinical significance of Volta Medical’s technology and lay the ground for establishing VX1 as a new standard of care for persistent AF ablation.

“The results of the Ev-AIFib trial show that Volta’s AI enhanced VX1 software is finally able to provide reliability and reproducibility in an EGM based approach – the holy grail of EGM based ablation approaches. The technology has shown a high potential to assist in treating the complex persistent AF patients,” said Prof. Dr. Isabel Deisenhofer, MD, head of electrophysiology at German Heart Centre Munich, and principial investigator of the international, multicenter TAILORED-AF trial. She continues: “In my experience, VX1 has been an extremely helpful tool, and I look forward to further explore and confirm the technology’s potential in the ongoing TAILORED-AF trial.”

About Ev-AIFib Trial
The EV-AIFib trial, a prospective, multicenter, non-randomized, study was designed to determine the feasibility and relevance of constructing standardized dispersion maps, so called ‘Volta VX1 maps’, to be used as a reference to operators conducting EGM-guided ablation of patients in persistent atrial fibrillation (AF), as well as the use of the VX1 technology for center-to-center standardization of dispersion mapping. In the trial physicians were provided with VX1 adjudications in real time and used their discretion to ablate where it was the most clinically relevant. Carried out in 8 different centers with 17 participating operators, the study compared the acute and long-term outcomes of 85 patients after ablation in regions exhibiting dispersion between a primary and satellite centers. At the primary center, operators were the most experienced at dispersion-based ablation, while satellite centers corresponded to hospitals where physicians had little experience at performing dispersion-based ablation. The results were also compared to a control group in which dispersion-guided ablation was performed visually by trained operators.

About Atrial Fibrillation (AF)
AF can be considered an “electrical storm” in the atria in which all synchronized activities have disappeared, and the necessary coordination of the contraction stops. This can lead to a number of symptoms including palpitations, shortness of breath and in some patients, heart failure.

AF affects approximately 33 million patients worldwide – a figure expected to double by 2030 driven by an aging population.1 Evidence suggests a higher prevalence of AF in patients with hypertension, heart failure, coronary heart disease, obesity and diabetes. In addition, recent studies show that 20-30% of patients with ischemic stroke have had AF before, during or after the initial event. AF is also a major risk factor for stroke, increasing the likelihood of stroke by four to five times, as stagnant blood in the atrium during AF may lead to the formation of a clot, which can migrate to the brain. In addition, AF-induced strokes are associated with more severe damage.

Common treatment for AF includes medication that regulates or slows the heart rate.2 For patients who cannot tolerate or who are resistant to anti-arrhythmic drug therapy, ablation is the current standard of care.2 Ablation uses heat or cold energy to create tiny scars in the heart to block abnormal electrical signals and restore a normal heartbeat.1 However, the efficacy of this approach depends to a large degree on the experience and intuition of the ablating physician.

About the Volta VX1 AI decision support software
VX1 consists of a highly innovative AI algorithm that is compatible with most readily available multipolar catheters and mapping technologies currently used in operating rooms or electrophysiology labs. VX1 is a medical device which is FDA cleared and has a CE mark. The FDA label reads “The VX1 assists operators in the real-time annotation of 3D anatomical and electrical maps of human atria for the presence of multipolar intra-cardiac atrial EGMs exhibiting specific abnormal EGM, known as dispersion, during atrial fibrillation or atrial tachycardia. The clinical significance of utilizing the VX1 software to help identify areas with intra-cardiac atrial EGMs exhibiting spatiotemporal dispersion for catheter ablation of atrial arrhythmias, such as atrial fibrillation, has not been established by clinical investigations.”

About Volta Medical
Founded by three physicians and a data scientist in 2016 in Marseille, Volta Medical is a health tech company developing artificial intelligence software solutions to assist cardiac electrophysiologists during arrhythmia treatment procedures. Volta’s overarching goal is to drastically improve cardiac arrhythmia management by developing state-of-the-art, data-driven medical devices trained on large databases of procedural data with the highest standards of data protection. Its first product, VX1, a digital AI companion device and algorithm assists cardiologists for the real-time identification of specific abnormal EGMs, known as dispersed EGMs.
For more information, visit the company’s website at www.volta-medical.com.


Media Contacts

Volta Medical
Jeff Martin, VP of Global Marketing
jeffrey.martin@volta-medical.com

U.S. Media Contact
FinnPartners
Glenn Silver
glenn.silver@finnpartners.com

Europe Media Contact
MC Services AG
Julia Bittner
julia.bittner@mc-services.eu

France Media Contact
Alize RP
Caroline Carmagnol
caroline@alizerp.com


References
1 Chugh SS, Havmoeller R, Narayannan K, et al. Worldwide epidemiology of atrial fibrillation: A global burden of
disease 2010 study. Circulation 2014; 129:837–8472
2 Mayo Clinic, Patient Care & Health Information, Tests & Procedures, Cardiac Ablation:
https://www.mayoclinic.org/tests-procedures/cardiac-ablation/about/pac-20384993

Volta Medical raises 23 million Euros to revolutionize persistent AF ablation

Volta Logo

Volta Medical raises 23 million Euros to revolutionize persistent AF ablation

Marseille, 7 January 2021 – Volta Medical, a pioneering French-based HealthTech startup, working on novel artificial intelligence (AI) algorithms to treat cardiac arrythmias, today announced that it has successfully raised 23 million Euros. The financing round was led by Gilde Healthcare with participation of existing shareholder Pasteur Mutualité. The new capital will allow the company to establish its revolutionary FDA-cleared and CE marked VX1 AI software solution as a new standard of care, pursue further R&D activities and start to roll out commercial activities across the US and Europe. Recruitment for TAILORED-AF, an international multicenter trial has already started. Volta Medical will be welcoming two new Board members. Janke Dittmer, General Partner at Gilde Healthcare, has been nominated as a board member and former medical device industry top executive, Denis Gestin, as an independent board member.

After developing the first commercially available AI software to help electrophysiologists improve management of cardiac arrythmias, Volta Medical is now preparing to transform the way ablation procedures will take place in the future. Theophile Mohr-Durdez, CEO and co-founder of Volta Medical mentioned: “We are excited to be able to complete our highly ambitious medical program with the start of TAILORED-AF, a new randomized controlled trial (RCT). This trial aims to demonstrate how our AI software can help physicians optimize both efficacy and efficiency when performing complex procedures to treat heart rhythm disturbances.” Atrial fibrillation (AF) currently affects over 30 million patients worldwide. This underlines the importance of the TAILORED-AF trial which is likely to result in a breakthrough approach for tackling one of the world’s greatest public health challenges in a more consistent and reproducible manner. According to Gilde Healthcare’s Janke Dittmer, “We are excited to support Volta’s team in bringing a unique solution to address one of the biggest unmet needs in the large and fast-growing electrophysiology market”.

About atrial fibrillation (AF)
AF can be considered an “electrical storm” in the atria in which all synchronized activities have disappeared, and the necessary coordination of the contraction stops. This can lead to a number of symptoms including palpitations, shortness of breath, and in some patients, heart failure. AF is also a major risk factor for stroke, as stagnant blood in the atrium during AF may lead the formation of a clot, that can migrate to the brain. AF increases the likelihood of stroke by four to five times and AFib-induced strokes that are generally associated with more severe damage.

AF is an extremely costly public health problem. It affected approximately 6 million patients in the US in 2019 and 11 million patients in Europe in 2018 and prevalence is estimated to double by 2060. In Europe 120,000-215,000 new cases are projected to occur each year reaching a total AF patient population prevalence of 14-17 million by 2030. Evidence suggests a higher prevalence of AF in patients with hypertension, heart failure, coronary heart disease, obesity, diabetes. In addition, recent studies show that 20-30% of patients with ischemic stroke have had AF before, during or after the initial event.

The TAILORED-AF trial
TAILORED-AF is an international, multicenter trial designed to compare the VX1 AI software ablation strategy with currently used conventional anatomical ablation approaches. According to Dr Tom De Potter, Head of Electrophysiology, OLV Hospital, Aalst, Belgium and one of the TAILORED-AF trial investigators, “treatment of the more severe forms of drug-resistant persistent AF remains a major challenge in our field, both due to the large number of patients affected and lack of therapeutic strategies that can offer predictable efficacy. Thanks to the software’s ability to identify signals that are relevant, from those that are less relevant, one of its greatest and most unique benefits is to allow for a more easily reproducible approach to ablation.” The results of the Ev-AIAFIB proof of concept study carried out with VX1 in 8 different centers will soon be published. They will provide data on why and how this new approach has the potential to provide electrophysiologists with a guidance tool that will optimize treatment of patients with AF in a lasting manner.

Conventional ablation methods, while useful for treating patients, who cannot tolerate or who are resistant to anti-arrhythmic drug therapy, have so far been less precise than desired. Their results, even if significant in certain cases, remain sub-optimal. Localization and ablation of drivers perpetuating AF have been at the forefront of cardiovascular disease research but have not led to any radical changes to-date. Volta’s system is intuitive, user-friendly and shows promise to potentially reduce inter-operator variability in the analysis of procedural data without lengthening either the diagnostic or therapeutic procedures. “We are eager to help new centers access and use our revolutionary tool during ablation procedures. This cutting-edge medical innovation enhances the efficiency and precision of the practitioners who are analyzing real-time data in the operating room. Its robustness will help physicians adopt a more efficient workflow and take the right decisions” – claimed physician co-founder, Jerome Kalifa.

About Volta Medical
Founded by three physicians and a data scientist in 2016 in Marseille, Volta Medical is a HealthTech company developing AI software solutions to assist cardiac electrophysiologists in the operating room. Volta’s overarching goal is to drastically improve cardiac arrythmia management by developing state-of-the-art, data-driven medical devices based on large databases of procedural data with the highest standards of data protection. Its first product, VX1, assists cardiologists for the real-time identification of specific abnormal electrograms, known as dispersed electrograms.
For more information, visit the company’s website at www.volta-medical.com.

About the VX1 AI software
VX1 consists of a highly innovative AI algorithm that is compatible with most readily available multipolar catheters and technologies currently used in operating rooms or electrophysiology labs. The VX1 software analyzes the patient’s electrograms in real-time to identify specific electrograms known as dispersed electrograms. It also provides a cycle length estimation from electrograms recorded with the mapping and the coronary sinus catheters.

The clinical significance of utilizing the VX1 software to help identify areas with intra-cardiac atrial electrograms exhibiting spatiotemporal dispersion for catheter ablation of atrial arrhythmias, such as atrial fibrillation, has not been established by clinical investigations.
VX1 is a medical device which is FDA cleared and has a CE mark.

About Gilde Healthcare
Gilde Healthcare is a specialized healthcare investor managing over €1.4 billion across two fund strategies: venture & growth capital and private equity. Gilde Healthcare’s venture & growth capital fund invests in fast growing companies active in digital health, MedTech and therapeutics. The venture & growth companies are based in Europe and North America. For more information, visit the company’s website at www.gildehealthcare.com.


Media Contacts
BCW agency
Linda Pavy – Tel: +33 (0)6 07 59 43 95 – Email: linda.pavy@bcw-global.com
Maëly Daviles – Tel: +33 (0)6 13 20 51 02 – Email: maely.daviles@bcw-global.com
Pauline Coudert – Tel +33 (0)6 88 38 46 58 – Email: pauline.coudert@bcw

References
1.https://globalheartjournal.com/articles/abstract/10.1016/j.gheart.2014.01.004/
2.https://www.ahajournals.org/doi/10.1161/strokeaha.115.012004
3.https://pubmed.ncbi.nlm.nih.gov/14966048/
4.Marco V. Perez, M.D., Kenneth W. Mahaffey, M.D., Haley Hedlin, Ph.D., John S. Rumsfeld, M.D., Ph.D., Ariadna Garcia, M.S., Todd Ferris, M.D., Vidhya Balasubramanian, M.S., Andrea M. Russo, M.D., Amol Rajmane, M.D., Lauren Cheung, M.D., Grace Hung, M.S., Justin Lee, M.P.H., et al., Large-Scale Assessment of a Smartwatch to Identify Atrial Fibrillation, N Engl J Med 2019; 381:1909-1917
5.https://www.jnjmedicaldevices.com/sites/default/files/2020-07/Burden%20of%20Disease%20Full%20report.pdf
6.Krijthe, Bouwe P., et al. “Projections on the number of individuals with atrial fibrillation in the European Union, from 2000 to 2060.” European heart journal 34.35 (2013): 2746-2751.
7.2017 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. European Heart Journal. 2016;37:2893–2962.doi:10.1093/eurheartj/ehw210
8.Authors/Task Force Members:, et al. “2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS.” EP Europace 18.11 (2016): 1609-1678.

Looking for new talent

Looking for new talents

Volta Medical brings together a team of top-talent dedicated to make a difference in the field of interventional cardiac electrophysiology.

Volta’s collaborators come from multiple countries and continents.

Our headquarters are located in Marseille. Marseille is in the South of France, on the Mediterranean sea. This creates a unique atmosphere, particularly prone to creativity and collaboration.

At Volta, we are convinced that everyone of us may contribute to improving the lives of patients with cardiac arrhythmias. This is what drives us to come to work every single day. Many of us also enjoy the natural scene and conviviality in Marseille. You may find us celebrating milestones nearby (or on!) the Mediterranean sea.

If you are inspired, feel free to reach out! We would love to review your application.

values-volta

Science

ABOUT Atrial Fibrillation

The heart beats are generated by the sino-atrial node, a small tissue region in the right atrium. The propagation of impulses to both upper chambers of the heart – i.e the two atria – causes them to contract and move the blood to the lower chambers of the heart, a.k.a the ventricles.

Atrial fibrillation (AF) is the most common heart rhythm disturbance in adults. AF is caused by abnormal electrical impulses forming anywhere in the atria. AF may be recorded on an electrocardiogram (ECG). The beating heart of AF patients is fast and irregular.

Physicians classify AF according to the duration of arrhythmia episodes. Brief episodes correspond to paroxysmal AF. Longer episodes are known as persistent AF.

ABOUT Interventional electrophysiology

Interventional electrophysiology is a surgical specialty. It requires multiple years of experience and consists of conducting intra-cardiac procedures to cure cardiac arrhythmias such as atrial fibrillation.

During an intervention, an electrophysiologist is required to analyze a large amount of information in real-time. First, an accurate visual analysis of up to 30 electrograms is essential. Then, non-electrogram information coming from multiple sources needs additional consideration.

All data allow for seamless progress through the multiple-step procedural workflow.

Bolt

Contact us

Office

EUROPE

Volta Medical
65 Avenue Jules Cantini
13006 Marseille
FRANCE

contact@volta-medical.com

View Map

Arrow
Office

USA

Volta Medical Inc
225 Dyer St, Providence
Rhode Island 02903
USA

contact@volta-medical.com

View Map

Arrow